🔹 Adj. EPS: $1.01 (est. $0.92) 🟢
🔹 Revenue: $4.78B (est. $4.66B) 🟢 (+3% YoY; +4% organic)
🔹 Net Income: $564M (+51% YoY)
🔹 Free Cash Flow: $98M (vs. $274M YoY)
Guidance (Updated):
🔹 FY25 Adj. EPS: $3.90–$4.10 (prior: $4.61–$4.75) 🔴
🔹 FY25 Adj. EBIT Margin: 14.2%–14.4% (prior: 16.7%–16.8%)
🔹 FY25 Organic Revenue Growth: 2%–3% (unchanged)
🔹 FY25 Free Cash Flow: ≥ $1.2B (prior: ≥ $1.75B) 🔴
🔹 Adj. ETR: 21%–22% (lowered)
Segment Performance (YoY Organic Growth):
🔹 Imaging: Rev $2.14B (+5%); EBIT Margin 9.3% (+130 bps)
🔹 Advanced Visualization: Rev $1.24B (+3%); EBIT Margin 21.1%
🔹 Patient Care Solutions: Rev $753M (+2%); EBIT Margin 6.4%
🔹 Pharmaceutical Diagnostics: Rev $632M (+8%); EBIT Margin 32.4% (+270 bps)
Strategic / Capital Updates:
🔸 $1B share repurchase program authorized
🔸 Closed acquisition of Nihon Medi-Physics to expand radiopharma capabilities
🔸 Launched Flyrcado™ (flurpiridaz F 18) in U.S., targeting cardiology imaging
CEO Commentary:
🔸 “Strong start to 2025 with solid revenue, orders, and profit growth. Despite macro uncertainty, demand remains robust.” — Peter Arduini, CEO
